Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Free Cash Flow (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Free Cash Flow readings, the most recent being -$14.3 million for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 5.03% to -$14.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$51.5 million, a 4.98% decrease, with the full-year FY2025 number at -$51.5 million, down 4.98% from a year prior.
  • Free Cash Flow hit -$14.3 million in Q4 2025 for Avalo Therapeutics, up from -$16.4 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $5.6 million in Q3 2022 to a low of -$19.2 million in Q2 2021.
  • Median Free Cash Flow over the past 5 years was -$12.0 million (2022), compared with a mean of -$11.5 million.
  • Biggest five-year swings in Free Cash Flow: soared 134.4% in 2022 and later tumbled 443.89% in 2024.
  • Avalo Therapeutics' Free Cash Flow stood at -$17.1 million in 2021, then surged by 76.97% to -$3.9 million in 2022, then grew by 29.8% to -$2.8 million in 2023, then tumbled by 443.89% to -$15.0 million in 2024, then increased by 5.03% to -$14.3 million in 2025.
  • The last three reported values for Free Cash Flow were -$14.3 million (Q4 2025), -$16.4 million (Q3 2025), and -$11.3 million (Q2 2025) per Business Quant data.